Delcath to Present at the ThinkEquity Partners' 5th Annual Growth Conference

NEW YORK--Sept. 17, 2007--Delcath Systems, Inc. (Nasdaq:DCTH) announced that its Chief Executive Officer, Richard L. Taney, will present this afternoon at the ThinkEquity Partners' 5th Annual Growth Conference, an annual symposium for the leaders of the growth economy that will feature over 200 presenting companies across the economy's top growth sectors, including life sciences, biotech, high tech, green tech, media, and consumer products and services. The Delcath presentation is scheduled for 2:00 PM Pacific Time. The event will be held at the St. Regis Hotel in San Francisco from September 17 - 20, 2007.

About Delcath Systems, Inc.
Delcath Systems is the developer of percutaneous perfusion technology for organ- or region-specific delivery of therapeutic and chemotherapeutic agents. The Delcath system is currently being tested with the drug melphalan in a Phase III trial of patients with metastatic ocular and cutaneous melanoma in the liver, and a Phase II trial of patients with primary liver cancers and metastatic tumors in the liver from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. The Company's intellectual property portfolio currently consists of 12 patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company's website www.delcath.com.